320 related articles for article (PubMed ID: 8563760)
1. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
Lindberg RL; Porcher C; Grandchamp B; Ledermann B; Bürki K; Brandner S; Aguzzi A; Meyer UA
Nat Genet; 1996 Feb; 12(2):195-9. PubMed ID: 8563760
[TBL] [Abstract][Full Text] [Related]
2. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
[TBL] [Abstract][Full Text] [Related]
3. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.
Johansson A; Nowak G; Möller C; Harper P
Mol Genet Metab; 2004 May; 82(1):20-6. PubMed ID: 15110317
[TBL] [Abstract][Full Text] [Related]
4. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria.
Lindberg RL; Martini R; Baumgartner M; Erne B; Borg J; Zielasek J; Ricker K; Steck A; Toyka KV; Meyer UA
J Clin Invest; 1999 Apr; 103(8):1127-34. PubMed ID: 10207164
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
Johansson A; Möller C; Fogh J; Harper P
Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
[TBL] [Abstract][Full Text] [Related]
6. Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties.
Ulbrichova D; Hrdinka M; Saudek V; Martasek P
FEBS J; 2009 Apr; 276(7):2106-15. PubMed ID: 19292878
[TBL] [Abstract][Full Text] [Related]
7. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
[TBL] [Abstract][Full Text] [Related]
8. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
Johansson A; Nowak G; Möller C; Blomberg P; Harper P
Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
[TBL] [Abstract][Full Text] [Related]
9. CRIM-positive mutations of acute intermittent porphyria in Finland.
Kauppinen R; Peltonen L; Pihlaja H; Mustajoki P
Hum Mutat; 1992; 1(5):392-6. PubMed ID: 1301948
[TBL] [Abstract][Full Text] [Related]
10. Purple pigments: the pathophysiology of acute porphyric neuropathy.
Lin CS; Lee MJ; Park SB; Kiernan MC
Clin Neurophysiol; 2011 Dec; 122(12):2336-44. PubMed ID: 21855406
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
Sardh E; Rejkjaer L; Andersson DE; Harper P
Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
[TBL] [Abstract][Full Text] [Related]
12. Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice.
Unzu C; Sampedro A; Mauleón I; González-Aparicio M; Enríquez de Salamanca R; Prieto J; Aragón T; Fontanellas A
Hum Mol Genet; 2013 Jul; 22(14):2929-40. PubMed ID: 23562909
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
[TBL] [Abstract][Full Text] [Related]
14. Hemodialysis: a therapeutic option for severe attacks of acute intermittent porphyria in developing countries.
Prabahar MR; Manorajan R; Sathiyakumar D; Soundararajan P; Jayakumar M
Hemodial Int; 2008 Jan; 12(1):34-8. PubMed ID: 18271838
[TBL] [Abstract][Full Text] [Related]
15. [Three new mutations in the porphobilinogen deaminase gene, detected in acute intermittent porphyria patients from Russia].
Surin VL; Luk'ianenko AV; Karpova IV; Misiurin AV; Pustovot IaS; Pivnik AV
Genetika; 2001 May; 37(5):690-7. PubMed ID: 11436563
[TBL] [Abstract][Full Text] [Related]
16. Acute intermittent porphyria.
Grandchamp B
Semin Liver Dis; 1998; 18(1):17-24. PubMed ID: 9516674
[TBL] [Abstract][Full Text] [Related]
17. Molecular study of the hydroxymethylbilane synthase gene (HMBS) among Polish patients with acute intermittent porphyria.
Gregor A; Schneider-Yin X; Szlendak U; Wettstein A; Lipniacka A; Rüfenacht UB; Minder EI
Hum Mutat; 2002 Mar; 19(3):310. PubMed ID: 11857754
[TBL] [Abstract][Full Text] [Related]
18. Neurological manifestations of acute intermittent porphyria.
Pischik E; Kauppinen R
Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):72-83. PubMed ID: 19268005
[TBL] [Abstract][Full Text] [Related]
19. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
[TBL] [Abstract][Full Text] [Related]
20. Correlation between biochemical findings, structural and enzymatic abnormalities in mutated HMBS identified in six Israeli families with acute intermittent porphyria.
Ulbrichova D; Schneider-Yin X; Mamet R; Saudek V; Martasek P; Minder EI; Schoenfeld N
Blood Cells Mol Dis; 2009; 42(2):167-73. PubMed ID: 19138865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
